| 0.072 0.008 (11.63%) | 10-24 14:41 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.08 | 1-year : | 0.11 |
| Resists | First : | 0.07 | Second : | 0.09 |
| Pivot price | 0.07 |
|||
| Supports | First : | 0.04 | Second : | 0.03 |
| MAs | MA(5) : | 0.06 |
MA(20) : | 0.06 |
| MA(100) : | 0.06 |
MA(250) : | 7.9  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 32.2 |
D(3) : | 36.7 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 37 | Low : | 0.03 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ HEPA ] has closed below upper band by 49.8%. Bollinger Bands are 28.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.08 - 0.08 | 0.08 - 0.08 |
| Low: | 0.06 - 0.06 | 0.06 - 0.06 |
| Close: | 0.06 - 0.06 | 0.06 - 0.06 |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Mon, 16 Jun 2025
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer - GlobeNewswire
Mon, 12 May 2025
Hepion Pharmaceuticals to be delisted from Nasdaq - Investing.com
Mon, 12 May 2025
Hepion Pharmaceuticals Initiates Transition to OTC Markets Following Nasdaq Delisting Notice - Nasdaq
Mon, 12 May 2025
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - Stock Titan
Mon, 12 May 2025
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 448 (K) |
| Shares Short P.Month | 200 (K) |
| EPS | -45.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -98.5 % |
| Return on Equity (ttm) | -368.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|